Tox: Organophosphate Poisoning (Cholinergic) for MRCP Part 1

TL;DR

Tox: Organophosphate Poisoning (Cholinergic) is a classic and frequently tested topic in MRCP Part 1. Candidates should recognise the cholinergic toxidrome quickly, distinguish muscarinic from nicotinic symptoms, and understand why atropine and pralidoxime are used together. Common examination traps include confusing cholinergic with anticholinergic toxicity and forgetting delayed complications such as intermediate syndrome.

Why Organophosphate Poisoning Matters in MRCP Part 1

Organophosphates are commonly used pesticides and insecticides. Toxic exposure may occur accidentally, occupationally, or intentionally. The syndrome is clinically important worldwide and frequently appears in undergraduate and postgraduate examinations.

MRCP questions commonly test:

• Cholinergic excess symptoms

• Mechanism of acetylcholinesterase inhibition

• Muscarinic versus nicotinic effects

• Atropine and pralidoxime indications

• Respiratory failure

• Delayed neurological complications

What Are Organophosphates?

Organophosphates inhibit the enzyme acetylcholinesterase. This causes accumulation of acetylcholine at synapses and neuromuscular junctions, leading to overstimulation of cholinergic receptors.

Common sources include:

1. Agricultural pesticides

2. Veterinary insecticides

3. Industrial chemicals

4. Nerve agents such as sarin

The mechanism is highly testable.

Pathophysiology

Normally, acetylcholinesterase breaks down acetylcholine after neurotransmission. Organophosphates phosphorylate the enzyme, preventing acetylcholine degradation.

The result is excessive stimulation of:

• Muscarinic receptors

• Nicotinic receptors

• Central nervous system cholinergic pathways

A particularly important examination concept is enzyme ageing.

What is ageing?

Over time, the organophosphate-enzyme bond becomes irreversible. Once ageing occurs, oxime therapy becomes much less effective.

This explains why pralidoxime should ideally be given early.

The Cholinergic Toxidrome

Recognising the cholinergic toxidrome is the key to solving most MRCP toxicology questions.

Muscarinic Features

The classic mnemonic is DUMBELS.

Mnemonic	Clinical Feature
D	Diarrhoea
U	Urination
M	Miosis
B	Bradycardia / Bronchorrhoea
E	Emesis
L	Lacrimation
S	Salivation

Additional muscarinic manifestations include:

• Wheeze

• Bronchospasm

• Hypotension

• Sweating

The presence of copious secretions is a major clue.

Nicotinic Features

These are commonly forgotten in examinations.

Important nicotinic manifestations include:

• Muscle fasciculations

• Weakness

• Paralysis

• Tachycardia

• Hypertension

Respiratory muscle paralysis is a major cause of mortality.

Central Nervous System Features

Patients may also develop:

• Confusion

• Agitation

• Seizures

• Coma

• Respiratory depression

The 5 Most Tested Subtopics

1. Atropine Therapy

Atropine is the cornerstone of treatment.

High-yield facts

• Atropine blocks muscarinic receptors

• It reduces bronchorrhoea and bronchospasm

• It does not reverse muscle paralysis

• Dosing is titrated to secretion control

A common MRCP trap is assuming that pupil dilation marks adequate treatment. In reality, the treatment endpoint is improvement in oxygenation and drying of respiratory secretions.

2. Pralidoxime (2-PAM)

Pralidoxime regenerates acetylcholinesterase before ageing occurs.

Important examination points

• Most effective if administered early

• Reverses neuromuscular dysfunction

• Improves muscle weakness

• Less effective after ageing

Questions frequently ask which drug improves fasciculations and paralysis. The answer is pralidoxime rather than atropine.

3. Respiratory Failure

Respiratory compromise is the leading cause of death.

Mechanisms include:

• Bronchorrhoea

• Bronchospasm

• Respiratory muscle weakness

• Central respiratory depression

Management priorities

1. Airway protection

2. Oxygen administration

3. Suction of secretions

4. Early intubation if necessary

4. Intermediate Syndrome

Intermediate syndrome occurs after apparent initial improvement, usually within 1–4 days.

Clinical features

• Neck flexor weakness

• Proximal muscle weakness

• Cranial nerve palsies

• Respiratory insufficiency

This delayed deterioration is highly testable.

5. Organophosphate-Induced Delayed Neuropathy

A delayed peripheral neuropathy may occur weeks later.

Features include:

• Distal weakness

• Paraesthesia

• Gait disturbance

This occurs through neuropathy target esterase inhibition rather than acute cholinergic excess.

Differential Diagnosis

MRCP Part 1 often tests toxidrome differentiation.

Condition	Key Distinguishing Feature
Anticholinergic toxicity	Dry skin and mydriasis
Opioid overdose	Pinpoint pupils without secretions
Myasthenic crisis	No muscarinic excess
Cholinergic crisis	Excess anticholinesterase medication
Carbamate poisoning	Reversible enzyme inhibition

Investigations

Diagnosis is usually clinical.

Supportive investigations include:

• Arterial blood gas

• ECG

• Plasma cholinesterase level

• Red cell acetylcholinesterase activity

Examination questions generally focus more on recognition and management than laboratory confirmation.

High-Yield Revision Checklist

Use this checklist during final revision:

• Learn the DUMBELS mnemonic thoroughly

• Distinguish muscarinic from nicotinic effects

• Know that atropine treats muscarinic symptoms only

• Remember pralidoxime reverses neuromuscular weakness

• Understand enzyme ageing

• Recognise intermediate syndrome

• Revise delayed neuropathy complications

• Prioritise airway management

• Differentiate cholinergic from anticholinergic toxidromes

• Practise toxicology MCQs repeatedly

For question-based learning, use the <a href="https://www.crackmedicine.com/mock-tests mock tests</a> and reinforce weak topics with the <a href=https://www.crackmedicine.com/lectures Part 1 lecture series</a>.

Practical Mini-Case

A 45-year-old farmer presents with sweating, vomiting, wheezing, diarrhoea, and pinpoint pupils after pesticide exposure. Examination reveals diffuse fasciculations and copious oral secretions.

Which treatment is most important immediately?

A. NaloxoneB. AtropineC. FlumazenilD. PhysostigmineE. Haloperidol

Answer: B. Atropine

This patient has classic organophosphate poisoning with a cholinergic toxidrome. Immediate management prioritises airway support and atropine administration to reduce bronchorrhoea and bronchospasm.

Why the other options are incorrect

• Naloxone treats opioid toxicity

• Flumazenil reverses benzodiazepines

• Physostigmine would worsen cholinergic excess

• Haloperidol has no role in acute management

Common MRCP Part 1 Pitfalls

• Forgetting nicotinic symptoms such as fasciculations

• Assuming atropine reverses paralysis

• Missing respiratory failure as the main cause of death

• Confusing cholinergic and anticholinergic toxidromes

• Forgetting delayed complications such as intermediate syndrome

Practical Exam Tips

How to recognise organophosphate poisoning rapidly

Look for the combination of:

• Pinpoint pupils

• Copious secretions

• Wheeze

• Fasciculations

• Bradycardia

Secretions are particularly important in distinguishing cholinergic toxicity from opioid overdose.

How MRCP questions are commonly framed

Questions often include:

• A farmer or pesticide exposure

• Respiratory distress with wheeze

• Excessive sweating or salivation

• Fasciculations

• Pinpoint pupils

The exam may then ask:

• Best initial treatment

• Mechanism of toxicity

• Drug mechanism

• Cause of respiratory failure

• Delayed complication

FAQs

Is atropine or pralidoxime more important initially?

Atropine is prioritised first because it rapidly improves life-threatening muscarinic symptoms such as bronchorrhoea and bronchospasm. Pralidoxime is added early to restore acetylcholinesterase activity.

Why can organophosphate poisoning cause both tachycardia and bradycardia?

Muscarinic stimulation produces bradycardia, while nicotinic stimulation at autonomic ganglia may produce tachycardia. Mixed cardiovascular findings can therefore occur.

What is intermediate syndrome?

Intermediate syndrome is delayed neuromuscular weakness occurring 1–4 days after acute poisoning. Respiratory failure may recur despite initial improvement.

How is organophosphate poisoning different from anticholinergic toxicity?

Organophosphate poisoning causes wet secretions, sweating, and miosis. Anticholinergic toxicity causes dry skin, urinary retention, hyperthermia, and dilated pupils.

Why is pralidoxime less effective later?

Over time, the organophosphate-enzyme complex undergoes ageing, making acetylcholinesterase inhibition irreversible.

Ready to start?

Organophosphate poisoning remains one of the most important toxicology topics in MRCP Part 1 because it tests physiology, pharmacology, emergency medicine, and clinical reasoning simultaneously.

Candidates should focus on:

• Recognising the cholinergic toxidrome

• Distinguishing muscarinic from nicotinic symptoms

• Understanding atropine and pralidoxime roles

• Anticipating respiratory failure

• Recognising delayed neurological complications

For structured revision, explore the <a href=https://www.crackmedicine.com/mrcp-part-1 Part 1 resource hub</a>, practise with the <a href=https://www.crackmedicine.com/qbankMRCP Question Bank</a>, and strengthen weak topics using the <a href=https://www.crackmedicine.com/lectures Medicine lecture library</a>.

Sources

1. MRCP(UK) Examination Blueprint

2. British National Formulary (BNF)

3. Davidson’s Principles and Practice of Medicine

4. Oxford Handbook of Clinical Medicine

5. TOXBASE Guidance on Organophosphate Poisoning

6. National Poisons Information Service — https://www.npis.org/

7. MRCP(UK) official website — https://www.mrcpuk.org/